CTR9-mediated JAK2/STAT3 pathway promotes the proliferation, migration, and invasion of human glioma cells

被引:5
作者
Xu, Yang [1 ]
Chen, Jiaguo [2 ]
He, Gao [3 ]
Zhang, Yuhai [1 ]
机构
[1] Nanjing Med Univ, Affiliated Brain Hosp, Dept Neurosurg, 264 Guangzhou Rd, Nanjing 210013, Peoples R China
[2] Nanjing Med Univ, Jinling Hosp, Dept Neurosurg, Nanjing, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Breast Dis Ctr, Nanjing, Peoples R China
关键词
CTR9; glioma; JAK2; pathway; STAT3; TYROSINE KINASE INHIBITORS; JAK-STAT PATHWAYS; PAF1; COMPLEX; CONSTITUTIVE ACTIVATION; SIGNALING PATHWAY; CANCER; CTR9; TRANSCRIPTION; COMPONENT; EGFR;
D O I
10.1002/jcla.23943
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background CTR9 (Cln three requiring 9) has been reported to be implicated in protein modification and oncogenesis of several human cancers. However, the protein expression and mechanism of CTR9 in glioma progression remain unclear. Methods We analyzed mRNA expression of CTR9 and CTR9-related survival curves in the public database. Then, we detected CTR9 expression in glioma tissues and constructed U251 and U87 cells with stable silencing or overexpression of CTR9. Cell function tests and Western blot were conducted to explore the effects of CTR9 on glioma proliferation, invasion and migration, and the specific mechanism. All the date was presented as means +/- SEM. Two-sample t test and one-way analysis of variance (ANOVA) were used to identify whether there was a significant difference between each group of data. Results We found that CTR9 was overexpressed in glioma and inversely associated with glioma patient survival. The results manifested that knockdown of CTR9 suppressed the proliferation, migration, and invasion of glioma cells, while overexpression facilitated them. The underlying molecular mechanism may involve the regulation of JAK2/STAT3 pathway by CTR9. Conclusion Our present study indicates that CTR9 is highly expressed in glioma and related to glioma grading and prognosis. CTR9 regulates malignant behaviors of glioma cells by activating JAK2/STAT3 pathway. Therefore, CTR9 may be a promising biomarker for the targeted therapy and prognosis evaluation of glioma.
引用
收藏
页数:10
相关论文
共 39 条
[1]  
Arevalo OJ., 2017, NEUROGRAPHICS, V7, p334
[2]   Ctr9, a Key Component of the Paf1 Complex, Affects Proliferation and Terminal Differentiation in the Developing Drosophila Nervous System [J].
Bahrampour, Shahrzad ;
Thor, Stefan .
G3-GENES GENOMES GENETICS, 2016, 6 (10) :3229-3239
[3]  
Bowles DW, 2013, DRUG TODAY, V49, P523, DOI [10.1358/dot.2013.49.09.2016610, 10.1358/dot.2013.49.9.2016610]
[4]   Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells [J].
Byun, Hyo Joo ;
Darvin, Pramod ;
Kang, Dong Young ;
Nipin, S. P. ;
Joung, Youn Hee ;
Park, Jong Hwan ;
Kim, Sun Jin ;
Yang, Young Mok .
ONCOLOGY REPORTS, 2017, 37 (06) :3270-3278
[5]   Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells [J].
Carloni, S. ;
Fabbri, F. ;
Brigliadori, G. ;
Ulivi, P. ;
Silvestrini, R. ;
Amadori, D. ;
Zoli, W. .
CURRENT CANCER DRUG TARGETS, 2010, 10 (04) :422-431
[6]   Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors [J].
Chi M. ;
Puzanov I. .
memo - Magazine of European Medical Oncology, 2012, 5 (4) :302-308
[7]   Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas [J].
Colomiere, M. ;
Ward, A. C. ;
Riley, C. ;
Trenerry, M. K. ;
Cameron-Smith, D. ;
Findlay, J. ;
Ackland, L. ;
Ahmed, N. .
BRITISH JOURNAL OF CANCER, 2009, 100 (01) :134-144
[8]   JAK-STAT PATHWAYS AND TRANSCRIPTIONAL ACTIVATION IN RESPONSE TO IFNS AND OTHER EXTRACELLULAR SIGNALING PROTEINS [J].
DARNELL, JE ;
KERR, IM ;
STARK, GR .
SCIENCE, 1994, 264 (5164) :1415-1421
[9]   IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling [J].
Fukui, H. ;
Zhang, X. ;
Sun, C. ;
Hara, K. ;
Kikuchi, S. ;
Yamasaki, T. ;
Kondo, T. ;
Tomita, T. ;
Oshima, T. ;
Watari, J. ;
Imura, J. ;
Fujimori, T. ;
Sasako, M. ;
Miwa, H. .
BRITISH JOURNAL OF CANCER, 2014, 111 (04) :763-771
[10]  
Ganguly D., 2018, ONCOTARGET, V9, P22095, DOI [10.18632/oncotarget.25188, DOI 10.18632/ONCOTARGET.25188]